Wanning rate of maternal-derived antibody against respiratory syncytial virus in children

Abstract

Dear Editor: One of the most dangerous pathogenic diseases in children, respiratory syncytial virus (RSV) causes severe morbidity and mortality [1]. Despite extensive studies in infectious immunobiology, clinical signs, diagnostic techniques, and animal models. The information from the sero-epidemiology study for RSV among the pediatric population is helpful in creating a public health strategy to correspond to the virus. In a nutshell, the mother’s antibodies may be transferred to the newborn through the placenta. There will be a waning of transmitted antibodies and a potential for new infection. It’s interesting to see how the seroprevalence of the antibody against RSV changes dynamically with age. In babies, RSV antibodies rapidly decline, and RSV infection subsequently increases anti-RSV IgG titers, according to a recent study. Children should be urged to get their RSV shots before they turn seven months old [2]. For the seroprevalence research for RSV, however, the diagnostic power of the laboratory instrument is a key concern in laboratory medicine. ELISA kits frequently still have limited sensitivity and a high percentage of false negatives, despite the fact that they are normally used widely [3]. In order to evaluate the results of a seropeidemiology inquiry, it is essential to take the influence of false negative into consideration. This article’s authors address the altered sero-epidemiology pattern of RSV antibodies among children in a country in Southeast Asia throughout a range of age groups. The EUROMIN ELISA test offers 96.2% sensitivity and 100% specificity based on the product data available, which implies 3.8% false negatives. 95.2% of people had IgG antibodies to RSV at birth [2]. The antibody starts to decline after birth and reaches its lowest point at 7 months of age, or 8.1%. The crude wanning rate will therefore be 87.1% every seven months or 12.4% per month. The adjusted wanning rate will be 11.9% per month following the erroneous negative adjustment. When the vaccine is released, this wanning pattern will provide helpful information for future immunization strategies. Acknowledgements Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.